Vcanbio Cell & Gene Engineering Corp., Ltd
SHH: 600645.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Hongqi Wang
- Employees
- 2,209
- Headquarters
- Tianjin, China
- IPO year
- 1993
- Market cap
- CN¥11.3B
- Website
- https://www.vcanbio.com
Loading 600645…
Loading profile data…Frequently asked questions about 600645
What does Vcanbio Cell & Gene Engineering Corp., Ltd (600645.SS) do?
Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, primarily engages in the preparation and storage of cell tests in the People's Republic of China. The company provides cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental sub totip...
Where does 600645.SS trade?
Vcanbio Cell & Gene Engineering Corp., Ltd (600645.SS) trades on the Shanghai Stock Exchange.
What sector is 600645.SS in?
Vcanbio Cell & Gene Engineering Corp., Ltd (600645.SS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Vcanbio Cell & Gene Engineering Corp., Ltd?
Hongqi Wang is the chief executive officer of Vcanbio Cell & Gene Engineering Corp., Ltd (600645.SS).
Where is Vcanbio Cell & Gene Engineering Corp., Ltd headquartered?
Vcanbio Cell & Gene Engineering Corp., Ltd is headquartered in China.
Does 600645.SS pay a dividend?
Vcanbio Cell & Gene Engineering Corp., Ltd (600645.SS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 600645.SS go public?
Vcanbio Cell & Gene Engineering Corp., Ltd (600645.SS) completed its initial public offering in 1993.